In resistant hypercholesterolemia, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors (evolocumab and alirocumab) are effective and safe choice, hence they do not alter glucose homeostasis and they do not trigger new onset of diabetes (194–196). This evidence concerns the gene PCSK9 and familial hypercholesterolemia.